reports
- MarketLine Department
C. R. Bard, Inc. - Mergers & Acquisitions (M&A), Partnerships & Allian...
Summary Marketline's C. R. Bard, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by C. R. Bard, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and...
- MarketLine Department
Antares Pharma, Inc. - Mergers & Acquisitions (M&A), Partnerships & Al...
Summary Marketline's Antares Pharma, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Antares Pharma, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the orga...
- MarketLine Department
Teleflex Incorporated - Mergers & Acquisitions (M&A), Partnerships & A...
Summary Marketline's Teleflex Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Teleflex Incorporated since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the o...
- Alex Morozov
Becton, Dickinson Delivers In-Line 2Q; Shares Trading Near Our FVE
Becton, Dickinson reported in-line fiscal second-quarter results, with revenue up 5.7% on a currency-neutral basis, including an estimated 80-basis-point adverse impact from the change in the U.S. dispensing business model. We're maintaining our $225 fair value estimate and narrow moat rating. All areas in the medical segment delivered good results, with the exception of medication management solutions, which was adversely affected by the U.S. dispensing revenue recognition change and a tough c...
- Alex Morozov
In-Line 3Q for BD; Valuation Unchanged
Becton, Dickinson and Co.’s third-quarter 2.4% organic revenue growth came mainly in line with our expectations. Our narrow-moat and stable trend ratings, as well as our $193 fair value estimate remain intact. The firm's currency-neutral comparable YTD 4.5% top-line growth positions Becton Dickinson in the lower end of the management fiscal year guidance. Within the Becton Dickinson medical segment, one of the main headwinds was the U.S. dispensing business model change. The management estimat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.